Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1992-1-9
pubmed:abstractText
A double-blind placebo-controlled prospective trial assessed the effect of a slow release formulation of bezafibrate (Bezalip Mono) on lipids, glucose homeostasis, platelet function and plasma fibrinogen in non-insulin dependent (type II) diabetics. Twenty-four patients completed the trial. There was a significant improvement in the cholesterol and triglyceride levels and in the fasting blood glucose and glycated haemoglobin levels of those who received the active preparation but not in those who received placebo. Treatment, but not placebo, also resulted in a significant fall in plasma fibrinogen concentration and a trend towards inhibition of platelet aggregation. Bezafibrate was well tolerated and only one patient withdrew from the trial possibly because of side-effects of the drug. A larger study is needed to establish whether bezafibrate can reduce non-lipid risk factors (e.g., plasma fibrinogen concentration; glucose intolerance--hyperinsulinaemia) in normo- and hyperlipidaemic patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Diphosphate, http://linkedlifedata.com/resource/pubmed/chemical/Bezafibrate, http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose, http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, http://linkedlifedata.com/resource/pubmed/chemical/Collagen, http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations, http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Nonesterified, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen, http://linkedlifedata.com/resource/pubmed/chemical/Lipids, http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, HDL, http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, LDL, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0265-5985
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
133-8
pubmed:dateRevised
2007-9-11
pubmed:meshHeading
pubmed-meshheading:2132185-Adenosine Diphosphate, pubmed-meshheading:2132185-Bezafibrate, pubmed-meshheading:2132185-Blood Glucose, pubmed-meshheading:2132185-Blood Platelets, pubmed-meshheading:2132185-Cholesterol, pubmed-meshheading:2132185-Collagen, pubmed-meshheading:2132185-Delayed-Action Preparations, pubmed-meshheading:2132185-Diabetes Mellitus, Type 2, pubmed-meshheading:2132185-Fatty Acids, Nonesterified, pubmed-meshheading:2132185-Female, pubmed-meshheading:2132185-Fibrinogen, pubmed-meshheading:2132185-Homeostasis, pubmed-meshheading:2132185-Humans, pubmed-meshheading:2132185-Lipids, pubmed-meshheading:2132185-Lipoproteins, HDL, pubmed-meshheading:2132185-Lipoproteins, LDL, pubmed-meshheading:2132185-Male, pubmed-meshheading:2132185-Middle Aged, pubmed-meshheading:2132185-Pilot Projects, pubmed-meshheading:2132185-Platelet Aggregation, pubmed-meshheading:2132185-Platelet Aggregation Inhibitors, pubmed-meshheading:2132185-Prospective Studies, pubmed-meshheading:2132185-Triglycerides
pubmed:year
1990
pubmed:articleTitle
The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
pubmed:affiliation
Dept. of Chemical Pathology and Human Metabolism, Royal Free Hospital, London, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial, Research Support, Non-U.S. Gov't